The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
The Lancet - Early Online Publication,  Evidence Based Medicine  Clinical Article

In individuals with 5–year risk of major vascular events lower than 10%, each 1 mmol/L reduction in LDL cholesterol produced an absolute reduction in major vascular events of about 11 per 1000 over 5 years. This benefit greatly exceeds any known hazards of statin therapy. Under present guidelines, such individuals would not typically be regarded as suitable for LDL–lowering statin therapy. The present report suggests, therefore, that these guidelines might need to be reconsidered.

Methods
  • This meta–analysis included individual participant data from 22 trials of statin versus control (n=134537; mean LDL cholesterol difference 1.08 mmol/L; median follow–up 4.8 years) and five trials of more versus less statin (n=39612; difference 0.51 mmol/L; 5.1 years).
  • Major vascular events were major coronary events (ie, non–fatal myocardial infarction or coronary death), strokes, or coronary revascularisations.
  • Participants were separated into five categories of baseline 5–year major vascular event risk on control therapy (no statin or low–intensity statin) (<5%, ≥5% to <10%, ≥10% to <20%, ≥20% to <30%, ≥30%); in each, the rate ratio (RR) per 1.0 mmol/L LDL cholesterol reduction was estimated.

Results
  • Reduction of LDL cholesterol with a statin reduced the risk of major vascular events (RR 0.79, 95% CI 0.77–0.81, per 1.0 mmol/L reduction), largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all–cause mortality.
  • The proportional reduction in major vascular events was at least as big in the two lowest risk categories as in the higher risk categories (RR per 1.0 mmol/L reduction from lowest to highest risk: 0.62 [99% CI 0.47–0.81], 0.69 [99% CI 0.60–0.79], 0.79 [99% CI 0.74–0.85], 0.81 [99% CI 0.77–0.86], and 0.79 [99% CI 0.74–0.84]; trend p=0.04), which reflected significant reductions in these two lowest risk categories in major coronary events (RR 0.57, 99% CI 0.36–0.89, p=0.0012, and 0.61, 99% CI 0.50–0.74, p<0.0001) and in coronary revascularisations (RR 0.52, 99% CI 0.35–0.75, and 0.63, 99% CI 0.51–0.79; both p<0.0001).
  • For stroke, the reduction in risk in participants with 5–year risk of major vascular events lower than 10% (RR per 1.0 mmol/L LDL cholesterol reduction 0.76, 99% CI 0.61–0.95, p=0.0012) was also similar to that seen in higher risk categories (trend p=0.3).
  • In participants without a history of vascular disease, statins reduced the risks of vascular (RR per 1.0 mmol/L LDL cholesterol reduction 0.85, 95% CI 0.77–0.95) and all–cause mortality (RR 0.91, 95% CI 0.85–0.97), and the proportional reductions were similar by baseline risk.
  • There was no evidence that reduction of LDL cholesterol with a statin increased cancer incidence (RR per 1.0 mmol/L LDL cholesterol reduction 1.00, 95% CI 0.96–1.04), cancer mortality (RR 0.99, 95% CI 0.93–1.06), or other non–vascular mortality.

Please login or register to follow this author.
► Click here to access PubMed, Publisher and related articles...

Your Unread Messages in Pharmacy

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Pharmacy Articles

1 New drug could make vaccines more effective in the elderly University of Oxford News, November 14, 2014

2 FDA approves new type of sleep drug, Belsomra Full Text FDA Press Announcements, August 14, 2014    Free full text

3 Antibiotic developed 50 years ago may be the key to fighting 'superbugs' University at Buffalo Health and Medicine News, June 19, 2014

4 One injection stops diabetes in its tracks Salk Institute News, July 18, 2014

5 'Unsung' cells double the benefits of a new osteoporosis drug Johns Hopkins Medicine, October 7, 2014

6 New research indicates statin drugs must be taken properly Michigan State University Health News, July 22, 2014

7 Statins reverse learning disabilities caused by genetic disorder UCLA Health System, November 18, 2014

8 UCLA researchers find that drug used for another disease slows progression of Parkinson's UCLA Health System, October 10, 2014

9 Opioid overdose cause for over 100,000 emergency department visits in 2010 Lifespan, November 12, 2014

10 Semen directly impairs effectiveness of microbicides that target HIV Gladstone Institutes News, November 14, 2014

11 Duke team brings life-saving function to ketchup packets Duke University Health & Medicine News, July 3, 2014

12 A new pathway discovered regulating autoimmune diseases Brigham and Women's Hospital, October 9, 2014

13 Effect of ginger (Zingiber officinale) on heavy menstrual bleeding: a placebo-controlled, randomized clinical trial Phytotherapy Research, October 13, 2014    Clinical Article

14 Daily aspirin use and prostate cancer–specific mortality in a large cohort of men with nonmetastatic prostate cancer Journal of Clinical Oncology, October 24, 2014    Clinical Article

15 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 24, 2014    Clinical Article

16 Ripasudil: first global approval Drugs, November 21, 2014    Clinical Article

17 Effect of prasugrel in patients with asthma: results of PRINA,a randomized, double-blind, placebo-controlled, cross-over study Journal of Thrombosis and Haemostasis, November 25, 2014

18 Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide–sensitive human hypertension Hypertension, November 24, 2014    Clinical Article

19 Magnesium should be given to all children presenting to hospital with acute severe asthma Paediatric Respiratory Reviews, October 15, 2014    Clinical Article

20 Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients American Journal of Transplantation, November 17, 2014    Clinical Article

Indexed Journals in Pharmacy: Expert Opinion in Pharmacotherapy, Formulary, U.S.Pharmacistmore